RS51885B - PYRIDIN [3,4-b] PYRAZINNES - Google Patents

PYRIDIN [3,4-b] PYRAZINNES

Info

Publication number
RS51885B
RS51885B RS20110363A RSP20110363A RS51885B RS 51885 B RS51885 B RS 51885B RS 20110363 A RS20110363 A RS 20110363A RS P20110363 A RSP20110363 A RS P20110363A RS 51885 B RS51885 B RS 51885B
Authority
RS
Serbia
Prior art keywords
group
independently selected
alkyl
alkynyl
substituted
Prior art date
Application number
RS20110363A
Other languages
English (en)
Serbian (sr)
Inventor
Christopher Phillips
Robert O. Hughes
Dafydd Rhys Owen
David Louis Brown
Yvette Marlene Fobian
John Nicholas Freskos
Steven Edward Heasley
Eric Jon Jacobsen
Todd Michael Maddux
Brent Virgil Mischke
John Majo Molyneaux
Joseph Blair Moon
Donald Joseph Rogier Jr.
Michael Brent Tollefson
John Keith Walker
David Graham Brown
Michael John Palmer
Andrew Simon Bell
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of RS51885B publication Critical patent/RS51885B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Epoxy Compounds (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

PIRIDIN$3,4-b] PIRAZINONI. Jedinjenje ili farmaceutski prihvatljiva so jedinjenja, naznačena time što jedinjenje ima strukturu Formule I:pri čemu:R2 je izabrana iz grupe koja sadrži aril i 3 do 10 člani heterociklil prsten, pri čemu navedeni R2 aril i heterociklil supstituenti mogu po izboru da budu supstituisani sa jednim ili više supstituenata nezavisno izabranih iz grupe koja sadrži halogen, cijano, nitro, okso, alkil, alkenil, alkinil, cikloalkil, -OR201, -C (O)R201, -OC (O)R201, -C (O)OR201, -NR201R202, -N(R201)C(O)R202, -C(O)NR201R202, -C(O)NR201C(O)R202, -SR201, -S (O)R201i -S (O)2R201; pri čemu navedeni alkil, alkenil i alkinil i cikloalkil supstituenti mogu po izboru da budu supstituisani sa jednim ili više supstituenata nezavisno izabranih iz grupe koja sadrži halogen, okso, -OR203 i -C (O)OR203;R201, R202 i R203 su nezavisno izabrane iz grupe koja sadrži vodonik i alkil grupu, pri čemu navedena alkil grupa može po izboru da bude supstituisana sa jednim ili više supstituenata nezavisno izabranih iz grupe koja sadrži halogen, hidroksi, alkoksi, karboksi i -C (O)NH2;R6A i R6B, zajedno sa azotom za koji su vezane, formiraju delimično ili potpuno zasićeni 3 do 14 člani heterociklil prsten, pri čemu heterociklil može po izboru da bude supstituisan sa jednim ili više supstituenata nezavisno izabranih iz grupe koja sadrži vodonik, halogen, okso, alkil, alkenil, alkinil, cijano, -OR601, -C (O)R601, -OC (O)R601, -C (O)OR601, -NR60IR602, -N(R60I)C(O)R602, -C(O)NR601R602, -C(O)NR60lC(O)R602, cikloalkil, aril i heterociklil grupu, pri čemu (a) navedeni alkil, alkenil, alkinil i cikloalkil supstituenti mogu po izboru da budu supstituisani sa jednim ili više supstituenata nezavisno izabranih iz grupe koja sadrži halogen, cijano, okso, -OR603, -C (O)R603, -C (O)OR603, -OC (O)R603, -NR603R604, -(R603)C(O)R604,-C(O)NR603R604, -C(O)NR603C(O)R604, -SR603, -S (O)R603, -S (O)2R603, -N(R603)S(O)2R604 i -S(O)2NR603R604, C(O)NR603C(O)R604, -SR603, -S (O)R603, -S (O)2R603, -N(R603)S(O)2R604 i -S(O)2NR603R604 grapu i (b) navedeni aril i heterociklil supstituenti mogu po izboru da budu supstituisani sa jednim ili više supstituenata nezavisno izabranih iz grupe koja sadrži halogen, alkil, alkenil, alkinil, cijano, okso, -OR601, -C (O)R601, -C (O)OR601, -OC (O)R601, -NR601R602, -N(R60l)C(O)R602, -C(O)NR601R602, -C(O)NR601C(O)R602, -SR601, -S (O)R602, -S(O)2R601,-N(R601)S(O)2R602 i -S(O)2NR601R602 grupu;R601, R602, R603 i R604 su nezavisno izabrane iz grupe koja sadrži vodonik, alkil, alkenil i alkinil grupu, pri čemu (a) navedena R601 i R602 alkil grupa može po izboru da bude supstituisana sa jednim ili više supstituenata nezavisno izabranih iz grupe koja sadrži halogen, cijano, hidroksi, karboksi, okso, alkinil, haloalkinil, hidroksialki
RS20110363A 2006-04-21 2007-04-10 PYRIDIN [3,4-b] PYRAZINNES RS51885B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79397106P 2006-04-21 2006-04-21

Publications (1)

Publication Number Publication Date
RS51885B true RS51885B (en) 2012-02-29

Family

ID=38431249

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20110363A RS51885B (en) 2006-04-21 2007-04-10 PYRIDIN [3,4-b] PYRAZINNES
RSP-2008/0484A RS20080484A (xx) 2006-04-21 2007-04-10 PIRIDIN[3,4-b] PIRAZINONI

Family Applications After (1)

Application Number Title Priority Date Filing Date
RSP-2008/0484A RS20080484A (xx) 2006-04-21 2007-04-10 PIRIDIN[3,4-b] PIRAZINONI

Country Status (42)

Country Link
US (1) US7902195B2 (xx)
EP (1) EP2013208B1 (xx)
JP (1) JP4436892B2 (xx)
KR (1) KR101061328B1 (xx)
CN (1) CN101454320B (xx)
AP (1) AP2408A (xx)
AR (1) AR060525A1 (xx)
AT (1) ATE513831T1 (xx)
AU (1) AU2007242555B2 (xx)
BR (1) BRPI0710658A2 (xx)
CA (1) CA2649775C (xx)
CR (1) CR10327A (xx)
CU (1) CU23777B7 (xx)
CY (1) CY1111739T1 (xx)
DK (1) DK2013208T3 (xx)
DO (1) DOP2007000080A (xx)
EA (1) EA014919B1 (xx)
EC (1) ECSP088803A (xx)
ES (1) ES2366239T3 (xx)
GT (1) GT200700035A (xx)
HK (1) HK1133875A1 (xx)
HR (1) HRP20110539T1 (xx)
IL (1) IL194591A (xx)
MA (1) MA30352B1 (xx)
ME (1) MEP23808A (xx)
MX (1) MX2008012456A (xx)
MY (1) MY148583A (xx)
NL (1) NL2000583C2 (xx)
NO (1) NO20084129L (xx)
NZ (1) NZ571540A (xx)
PA (1) PA8724201A1 (xx)
PE (1) PE20080192A1 (xx)
PL (1) PL2013208T3 (xx)
RS (2) RS51885B (xx)
SI (1) SI2013208T1 (xx)
SV (1) SV2008003074A (xx)
TN (1) TNSN08408A1 (xx)
TW (1) TWI337609B (xx)
UA (1) UA92637C2 (xx)
UY (1) UY30291A1 (xx)
WO (1) WO2007122466A1 (xx)
ZA (1) ZA200808283B (xx)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51885B (en) 2006-04-21 2012-02-29 Pfizer Products Inc. PYRIDIN [3,4-b] PYRAZINNES
DK2101777T3 (en) * 2006-12-12 2015-08-17 Gilead Sciences Inc COMPOSITION FOR TREATMENT OF PULMONAL HYPERTENSION
BRPI0908569B8 (pt) 2008-03-05 2021-05-25 Merck Patent Gmbh estimuladores de secreção de insulina derivados de piridopirazinonas, seu uso, e composição farmacêutica
TW201020233A (en) * 2008-10-09 2010-06-01 Kyorin Seiyaku Kk Isoquinoline derivative, and pde inhibitor comprising same as active ingredient
NZ599549A (en) * 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
EP2637664B1 (en) 2010-10-15 2017-03-29 Gilead Sciences, Inc. Compositions and methods of treating pulmonary hypertension
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
WO2013164730A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
CA2882389A1 (en) 2012-09-20 2014-03-27 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014091352A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
CA2893333C (en) 2012-12-19 2017-10-24 Pfizer Inc. Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
JP2016507551A (ja) 2013-02-13 2016-03-10 ファイザー・インク ヘテロアリール置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
MD20150071A2 (ro) 2013-02-19 2016-02-29 Pfizer Inc. Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
EP3052495B1 (en) 2013-10-04 2019-06-26 Pfizer Inc Novel bicyclic pyridinones as gamma-secretase modulators
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
CA2944308A1 (en) 2014-04-01 2015-10-08 Pfizer Inc. Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
MA39866A (fr) 2014-04-10 2017-02-15 Pfizer Amides 2-amino-6-méthyl-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yle
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
JP6506833B2 (ja) 2014-08-06 2019-04-24 ファイザー・インク イミダゾピリダジン化合物
EA033423B1 (ru) 2015-02-03 2019-10-31 Pfizer Циклопропанбензофуранилпиридопиразиндионы
DK3766885T3 (da) 2015-06-17 2022-08-01 Pfizer Tricykliske forbindelser og deres anvendelse som phoshodiesteraseinhibitorer
JP2018531923A (ja) 2015-09-24 2018-11-01 ファイザー・インク Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
EP3353174A1 (en) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
AU2017223132B2 (en) 2016-02-23 2019-12-05 Pfizer Inc. 6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
CN109641898B (zh) 2016-07-01 2022-04-08 辉瑞公司 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物
CN110944998B (zh) 2017-06-22 2022-08-16 辉瑞大药厂 二氢-吡咯并-吡啶衍生物
WO2019005980A1 (en) * 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
HUE061533T2 (hu) 2018-03-23 2023-07-28 Pfizer Piperazin azaspiro származékok

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1361652A (fr) 1963-06-21 1964-05-22 Ciba Geigy Procédé de préparation de diazines, entre autres de la 2-méthyl-6-hydroxy-7-morpholino-ptéridine
DK0556393T3 (da) * 1990-11-06 2000-10-16 Yamanouchi Pharma Co Ltd Tilkondenseret pyrazinderivat
TW274550B (xx) * 1992-09-26 1996-04-21 Hoechst Ag
JP2000154139A (ja) 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
US6369056B1 (en) * 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6465465B1 (en) * 2000-03-14 2002-10-15 Arzneimittelwerk Dresden Gmbh Process for the treatment of erectile dysfunction and product therefor
EP1364950A4 (en) * 2001-02-26 2005-03-09 Tanabe Seiyaku Co PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US7067658B2 (en) * 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
JP2007504283A (ja) * 2003-05-20 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア β−アミロイド斑に作用物質を結合させる方法
JP4705912B2 (ja) * 2003-06-26 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション ベンゾジアゼピンｃｇｒｐ受容体拮抗物質
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
EP1833803A4 (en) * 2005-01-03 2009-08-05 Myriad Genetics Inc PHARMACEUTICAL COMPOUNDS COMPRISING CASPASE ACTIVATORS AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
WO2006126082A2 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2007022638A1 (en) * 2005-08-26 2007-03-01 Methylgene Inc. Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
RS51885B (en) 2006-04-21 2012-02-29 Pfizer Products Inc. PYRIDIN [3,4-b] PYRAZINNES

Also Published As

Publication number Publication date
WO2007122466A1 (en) 2007-11-01
ZA200808283B (en) 2009-11-25
HK1133875A1 (en) 2010-04-09
EA014919B1 (ru) 2011-04-29
CR10327A (es) 2008-10-21
PA8724201A1 (es) 2009-08-26
MEP23808A (en) 2010-06-10
CN101454320A (zh) 2009-06-10
DOP2007000080A (es) 2007-11-15
EA200801998A1 (ru) 2009-04-28
AU2007242555A1 (en) 2007-11-01
PL2013208T3 (pl) 2011-10-31
AP2408A (en) 2012-05-30
CN101454320B (zh) 2012-12-19
CA2649775C (en) 2011-05-31
CU20080194A7 (es) 2011-03-21
IL194591A (en) 2012-07-31
TWI337609B (en) 2011-02-21
NO20084129L (no) 2008-10-29
MA30352B1 (fr) 2009-04-01
ATE513831T1 (de) 2011-07-15
KR20080110930A (ko) 2008-12-19
CA2649775A1 (en) 2007-11-01
DK2013208T3 (da) 2011-08-15
ECSP088803A (es) 2008-11-27
AR060525A1 (es) 2008-06-25
US20070249615A1 (en) 2007-10-25
HRP20110539T1 (hr) 2011-08-31
PE20080192A1 (es) 2008-03-01
TNSN08408A1 (fr) 2010-04-14
BRPI0710658A2 (pt) 2011-08-16
AP2008004640A0 (en) 2008-10-31
US7902195B2 (en) 2011-03-08
GT200700035A (es) 2008-02-05
NL2000583A1 (nl) 2007-10-23
MY148583A (en) 2013-04-30
MX2008012456A (es) 2008-10-10
TW200808794A (en) 2008-02-16
JP4436892B2 (ja) 2010-03-24
CY1111739T1 (el) 2015-10-07
NL2000583C2 (nl) 2007-12-14
UA92637C2 (xx) 2010-11-25
UY30291A1 (es) 2007-11-30
JP2009534368A (ja) 2009-09-24
EP2013208A1 (en) 2009-01-14
SI2013208T1 (sl) 2011-09-30
CU23777B7 (es) 2012-02-15
AU2007242555B2 (en) 2010-12-16
NZ571540A (en) 2010-10-29
EP2013208B1 (en) 2011-06-22
RS20080484A (xx) 2009-07-15
KR101061328B1 (ko) 2011-08-31
SV2008003074A (es) 2010-01-12
ES2366239T3 (es) 2011-10-18

Similar Documents

Publication Publication Date Title
RS51885B (en) PYRIDIN [3,4-b] PYRAZINNES
RS54260B1 (en) AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT
RS52562B (en) (3-ARIL-PIPERAZINE-1-IL) DERIVATI 6,7-DIALCOKSIQUINZOLINE, 6,7-DIALCOKSIFTALAZINE I
RS52010B (en) DERIVATI PIROLO [2, 3-B] PIRIDINA KAO INHIBITORI PROTEIN KINAZE
RS53275B (en) ARYL-PYRIDINE AS AN ALDOSTERON SYNTHASE INHIBITOR
HRP20080064T5 (en) Prodrugs of piperazine and substituted piperidine antiviral agents
RS54735B1 (sr) Tretman za lipodistrofiju
HRP20070510T3 (en) Benzimidazole derivative and its use as a ii receptor antagonist
RS54429B1 (en) THE TETRAHYDROisoquinolin-1-ONE DERIVATIVE, OR IS
WO2008006625A3 (en) Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
RS53244B (en) 1`-SUBSTITUTED-CARB-NUCLEOSIDE PROTECTION FOR ANTI-VIRUS TREATMENT
RS54446B1 (en) PIROLOBENZIDIAZEPINE AND ITS CONJUGATES
MA28685B1 (fr) Derives de la quinazolinone, antagonistes de la vanilloide
MX2010005109A (es) Compuestos herbicidas.
NO20092279L (no) Makrocyklisk factor VIIa inhibitorer anvendbare som antikoagulanter
MX2015008971A (es) Derivados de pirimidina pirido- o pirrolo-fusionados como inhibidores de autotaxina para tratar dolor.
RS52203B (en) PYRAZOLINE COMPOUNDS AS ANTAGONISTS OF MINERALOCORTICOID RECEPTORS
RS53831B1 (en) Pyrazoloquinoline Derivates As DNA-PK Inhibitors
UA109525C2 (xx) Алкіламідна сполука і її застосування
MX344529B (es) Derivados antibioticos de 2 - oxo -oxazolidin - 3, 5 -diilo.
DK2040703T3 (da) Derivater af 2-benzoylimidazopyridiner, fremstilling deraf og terapeutisk anvendelse deraf
WO2009095792A3 (en) Substituted heteroarylamide diazepinopyrimidone derivatives
RS52518B (en) 4-ALCOXYPYRIDASINE DERIVATIVES AS A FAST DISSOCATING DOPAMINE 2 RECEPTOR ANTAGONISTS
RS51462B (en) TRIAZOLOPYRIDINE CARBOXAMID DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION
MX2010012303A (es) Agonista de receptor de glucocorticoide compuesto de derivado de 2,2,4-trimetil-6-fenil-1,2-dihidroquinolina que tiene un grupo oxi sustituido.